Ketamine therapy can reduce depression symptoms and suicidal thoughts: review
Marijuana Stocks, Finance, & InvestingUncategorized December 29, 2021 MJ Shareholders
A systematic review of dozens of research papers has found that ketamine therapy has a quick, short-term effect of reducing depression symptoms and suicidal thoughts, making it a promising mental health treatment alternative.
The U.K’s University of Exeter, in collaboration with the University of British Columbia, examined 33 systematic reviews, 29 randomized control trials, and 21 observational studies.
In a paper published in the British Journal of Psychiatry Open, they found the strongest evidence around the use of ketamine to treat both major depression and bipolar depression, with symptoms reduced as quickly as one to four hours after a single treatment that lasted up to two weeks.
The review also found that single or multiple doses of ketamine resulted in large reductions in suicidal thoughts, from four hours after the treatment and onward. The effect lasted on average three days, and up to one week, according to a news release.
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers